Xilio Therapeutics, Inc. (XLO) AI Dilution Summary

Cash was $136,040,000 at 2026-06-30, against estimated monthly burn of $6,850,833. The funding channel in use is the ATM program with Leerink Partners LLC, authorised to $14,500,000. Since the program began, 592,300 shares have been sold through 2026-06-30, and sales after 2026-06-30 are not yet reported.